Zimmer Biomet (ZBH) Q3 Earnings Surpass Estimates

Company Performance - Zimmer Biomet reported quarterly earnings of $1.9 per share, exceeding the Zacks Consensus Estimate of $1.88 per share, and up from $1.74 per share a year ago, representing an earnings surprise of +1.06% [1] - The company posted revenues of $2 billion for the quarter ended September 2025, which was below the Zacks Consensus Estimate by 0.42%, but an increase from $1.82 billion year-over-year [2] - Over the last four quarters, Zimmer has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - Zimmer shares have declined approximately 2.3% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.39 on revenues of $2.23 billion, and for the current fiscal year, it is $8.15 on revenues of $8.22 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]